Managers / Q3 2022 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$180M
Q3 2022
Positions
41
Filings on Record
30
2019–present window
Filed
Nov 4, 2022
original filing
Summary
Sivik Global Healthcare LLC reported $180M in U.S.-listed holdings across 41 positions for Q3 2022.
Its largest position, HCA, represents 4.3% of the portfolio.
Compared with Q2 2022, the fund opened 7 new positions and exited 4.
Portfolio Metrics
Turnover
+20.3%
vs prior filed quarter
Top-10 Concentration
+37.4%
share of reported value
Largest Position
+4.3%
Hca Healthcare
New / Exited
7 / 4
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 97.3% · $175M
- ADR · 2.2% · $4M
- ETP · 0.5% · $895,000
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| WATWaters Corp | NEW | +15.0K | 15.0K | +$4M | $4M |
| RVTYPerkinElmer Inc | NEW | +25.0K | 25.0K | +$3M | $3M |
| BIIBBiogen Inc | NEW | +10.0K | 10.0K | +$3M | $3M |
| RPRXRoyalty Pharma PLC | NEW | +45.0K | 45.0K | +$2M | $2M |
| AMEDAmedisys Inc | NEW | +17.5K | 17.5K | +$2M | $2M |
| INCYIncyte Corp | NEW | +18.8K | 18.8K | +$1M | $1M |
| EHABUSDEnhabit Inc | NEW | +62.6K | 62.6K | +$879,000 | $879,000 |
| SNYSanofi | SOLD OUT | −75.0K | 0 | −$4M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
41 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | HCAHCA Healthcare Inchistory → | Cash Securities | 4.34% | $8M | 42.5K |
| 2 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 4.23% | $8M | 15.0K |
| 3 | BSXBoston Scientific Corphistory → | Cash Securities | 3.98% | $7M | 185.0K |
| 4 | CICigna Corphistory → | Cash Securities | 3.86% | $7M | 25.0K |
| 5 | BAXBaxter International Inchistory → | Cash Securities | 3.59% | $6M | 120.0K |
| 6 | DHRDanaher Corphistory → | Cash Securities | 3.59% | $6M | 25.0K |
| 7 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 3.49% | $6M | 60.0K |
| 8 | THCTenet Healthcare Corphistory → | Cash Securities | 3.44% | $6M | 120.0K |
| 9 | SYKStryker Corphistory → | Cash Securities | 3.43% | $6M | 30.5K |
| 10 | JNJJohnson & Johnsonhistory → | Cash Securities | 3.40% | $6M | 37.5K |
| 11 | AAgilent Technologies Inchistory → | Cash Securities | 3.38% | $6M | 50.0K |
| 12 | UNHUnitedHealth Group Inchistory → | Cash Securities | 3.37% | $6M | 12.0K |
| 13 | MCKMcKesson Corphistory → | Cash Securities | 3.31% | $6M | 17.5K |
| 14 | UHSUniversal Health Services Inchistory → | Cash Securities | 3.19% | $6M | 65.0K |
| 15 | LLYEli Lilly & Cohistory → | Cash Securities | 3.14% | $6M | 17.5K |
| 16 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 3.12% | $6M | 30.0K |
| 17 | ACHCAcadia Healthcare Co Inchistory → | Cash Securities | 3.04% | $5M | 70.0K |
| 18 | CAHCardinal Health Inchistory → | Cash Securities | 2.96% | $5M | 80.0K |
| 19 | HUMHumana Inchistory → | Cash Securities | 2.83% | $5M | 10.5K |
| 20 | ELVElevance Health Inchistory → | Cash Securities | 2.78% | $5M | 11.0K |
| 21 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.59% | $5M | 55.0K |
| 22 | CORAmerisourceBergen Corphistory → | Cash Securities | 2.26% | $4M | 30.0K |
| 23 | WATWaters Corphistory → | Cash Securities | 2.25% | $4M | 15.0K |
| 24 | NVONovo Nordisk A/Shistory → | Cash Securities | 2.21% | $4M | 40.0K |
| 25 | CNCCentene Corphistory → | Cash Securities | 2.16% | $4M | 50.0K |
| 26 | EHCEncompass Health Corphistory → | Cash Securities | 2.14% | $4M | 85.0K |
| 27 | OPCHOption Care Health Inchistory → | Cash Securities | 1.92% | $3M | 110.0K |
| 28 | SGRYSurgery Partners Inchistory → | Cash Securities | 1.80% | $3M | 138.6K |
| 29 | RVTYPerkinElmer Inchistory → | Cash Securities | 1.67% | $3M | 25.0K |
| 30 | ABTAbbott Laboratorieshistory → | Cash Securities | 1.61% | $3M | 30.0K |
| 31 | S24Select Medical Holdings Corphistory → | Cash Securities | 1.60% | $3M | 130.0K |
| 32 | BIIBBiogen Inchistory → | Cash Securities | 1.48% | $3M | 10.0K |
| 33 | MDTMedtronic PLChistory → | Cash Securities | 1.35% | $2M | 30.0K |
| 34 | AVTRAvantor Inchistory → | Cash Securities | 1.09% | $2M | 100.0K |
| 35 | IQVIQVIA Holdings Inchistory → | Cash Securities | 1.01% | $2M | 10.0K |
| 36 | RPRXRoyalty Pharma PLChistory → | Cash Securities | 1.00% | $2M | 45.0K |
| 37 | AMEDAmedisys Inc | Cash Securities | 0.94% | $2M | 17.5K |
| 38 | Seagen Inc | Cash Securities | 0.76% | $1M | 10.0K |
| 39 | INCYIncyte Corp | Cash Securities | 0.69% | $1M | 18.8K |
| 40 | XBISPDR S&P Biotech ETF | Cash Securities | 0.50% | $895,000 | 11.3K |
| 41 | EHABUSDEnhabit Inc | Cash Securities | 0.49% | $879,000 | 62.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.